This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salvesen, H. B. Articles by Akslen, L. A. Search for Related Content PubMed PubMed Citation Articles by Salvesen, H. B. Articles by Akslen, L. A. Social Bookmarking                            What's this?

Prognostic Significance of Angiogenesis and Ki-67, p53, and p21 Expression: A Population-Based Endometrial Carcinoma Study

From the Department of Pathology, The Gade Institute, and the Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway.

Address reprint requests to Helga B Salvesen, MD, Department of Human Genetics, The University of Chicago, J.F. Knapp Medical Center, 924 E 57th St, Chicago, IL 60637; email hsalvese@ genetics.uchicago.edu.

PURPOSE: For endometrial carcinoma patients, there is a need for improved identification of high-risk groups that may benefit from postoperative adjuvant therapy. We therefore studied the prognostic impact of markers for cell proliferation, cell-cycle regulation, and angiogenesis among endometrial carcinoma patients in a population-based setting.

PATIENTS AND METHODS: All patients diagnosed with endometrial carcinoma between 1981 and 1985 in Hordaland County, Norway, were studied. The median follow-up for the survivors was 11.5 years (range, 8 to 15 years), with no patient lost because of insufficient follow-up information. Paraffin-embedded tumor tissue, available in 96% of the cases (n = 142), was studied immunohistochemically for microvessel density (MVD) and expression of Ki-67, p53, and p21 proteins. We used the hot spot method for calculation of MVD, and expression of Ki-67 and p21 protein, because this approach may increase the probability of detecting small aggressive clones of possible prognostic relevance. The importance of these tumor markers was investigated in univariate survival analyses and Cox regression analysis.

RESULTS: The majority of traditional clinicopathologic variables was significantly associated with the tumor biomarkers. Age, International Federation of Gynecology and Obstetrics (FIGO) stage, histologic type, histologic grade, MVD, as well as Ki-67, p53, and p21 protein expression, all significantly influenced survival in univariate analyses (P .05). In the Cox regression analysis, age, FIGO stage, MVD, Ki-67 expression, and p53 expression were the only variables with independent prognostic impact (P .05), whereas histologic type, histologic grade, and p21 expression had no independent influence. A group of high-risk patients with more than one unfavorable marker was identified.

CONCLUSION: In addition to age and FIGO stage, MVD, Ki-67, and p53 protein expression showed an independent prognostic impact. Thus, information derived from routine histologic specimens identified a subgroup of high-risk endometrial carcinoma patients in this population-based study.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. B. Salvesen, S. L. Carter, M. Mannelqvist, A. Dutt, G. Getz, I. M. Stefansson, M. B. Raeder, M. L. Sos, I. B. Engelsen, J. Trovik, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation PNAS, March 24, 2009; 106(12): 4834 - 4839. [Abstract] [Full Text] [PDF]

				N Horree, P J van Diest, P van der Groep, D M D S Sie-Go, and A P M Heintz Progressive derailment of cell cycle regulators in endometrial carcinogenesis J. Clin. Pathol., January 1, 2008; 61(1): 36 - 42. [Abstract] [Full Text] [PDF]

				R. A. Burger Experience With Bevacizumab in the Management of Epithelial Ovarian Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2902 - 2908. [Abstract] [Full Text] [PDF]

				I. M. Stefansson, H. B. Salvesen, and L. A. Akslen Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res., March 15, 2006; 66(6): 3303 - 3309. [Abstract] [Full Text] [PDF]

				Y.-T. Jeon, S. Kang, D.-H. Kang, K.-Y. Yoo, I.-A. Park, Y.-J. Bang, J. W. Kim, N.-H. Park, S.-B. Kang, H.-P. Lee, et al. Cyclooxygenase-2 and p53 Expressions in Endometrial Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1538 - 1542. [Abstract] [Full Text] [PDF]

				I. M. Stefansson, H. B. Salvesen, and L. A. Akslen Prognostic Impact of Alterations in P-Cadherin Expression and Related Cell Adhesion Markers in Endometrial Cancer J. Clin. Oncol., April 1, 2004; 22(7): 1242 - 1252. [Abstract] [Full Text] [PDF]

				O. Straume, P. O. Chappuis, H. B. Salvesen, O. J. Halvorsen, S. A. Haukaas, J. R. Goffin, L. R. Begin, W. D. Foulkes, and L. A. Akslen Prognostic Importance of Glomeruloid Microvascular Proliferation Indicates an Aggressive Angiogenic Phenotype in Human Cancers Cancer Res., December 1, 2002; 62(23): 6808 - 6811. [Abstract] [Full Text] [PDF]

				O. Straume and L. A. Akslen Importance of Vascular Phenotype by Basic Fibroblast Growth Factor, and Influence of the Angiogenic Factors Basic Fibroblast Growth Factor/Fibroblast Growth Factor Receptor-1 and Ephrin-A1/EphA2 on Melanoma Progression Am. J. Pathol., March 1, 2002; 160(3): 1009 - 1019. [Abstract] [Full Text] [PDF]

				I. Stefansson, L. A. Akslen, N. MacDonald, A. Ryan, S. Das, I. J. Jacobs, and H. B. Salvesen Loss of hMSH2 and hMSH6 Expression Is Frequent in Sporadic Endometrial Carcinomas with Microsatellite Instability: A Population-based Study Clin. Cancer Res., January 1, 2002; 8(1): 138 - 143. [Abstract] [Full Text] [PDF]

				O. Straume and L. A. Akslen Expresson of Vascular Endothelial Growth Factor, Its Receptors (FLT-1, KDR) and TSP-1 Related to Microvessel Density and Patient Outcome in Vertical Growth Phase Melanomas Am. J. Pathol., July 1, 2001; 159(1): 223 - 235. [Abstract] [Full Text] [PDF]

				H. B. Salvesen, N. MacDonald, A. Ryan, O. E. Iversen, I. J. Jacobs, L. A. Akslen, and S. Das Methylation of hMLH1 in a Population-based Series of Endometrial Carcinomas Clin. Cancer Res., September 1, 2000; 6(9): 3607 - 3613. [Abstract] [Full Text]

				N. D. MacDonald, H. B. Salvesen, A. Ryan, O.-E. Iversen, L. A. Akslen, and I. J. Jacobs Frequency and Prognostic Impact of Microsatellite Instability in a Large Population-based Study of Endometrial Carcinomas Cancer Res., March 1, 2000; 60(6): 1750 - 1752. [Abstract] [Full Text]

				H. B. Salvesen, S. Das, and L. A. Akslen Loss of Nuclear p16 Protein Expression Is Not Associated with Promoter Methylation but Defines a Subgroup of Aggressive Endometrial Carcinomas with Poor Prognosis Clin. Cancer Res., January 1, 2000; 6(1): 153 - 159. [Abstract] [Full Text]